Back to Top
Ichorbio Citations
Please see below for a full list of ichorbio publications arranged in date order. ichorbio currently has 32 citations in total.
| Year of Publication | Article Title | Journal Name | Authors | ichorbio Product Cited |
| 2024 | T cell help induces Myc transcriptional bursts in germinal center B cells during positive selection | Science Immunology, Volume 9 | Issue 93 | Ben Tikva et al. | ICH1042 |
| 2024 | Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models | Cancers 2024, 16(5), 1021 | Ye et al. | ICH1096 |
| 2024 | TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes | Nat Commun 15, 1337 | Mine et al. | ICH1110 |
| 2024 | Interferon-stimulated neutrophils as a predictor of immunotherapy response | Cancer Cell 42, 253–265 | Benguigui et al. | ICH1132 |
| 2024 | TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes | Nat Commun 15, 1337 | Mine et al. | ICH1135 |
| 2024 | Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut | mBio | Gaifem et al. | ICH2243 |
| 2024 | Interferon-stimulated neutrophils as a predictor of immunotherapy response | Cancer Cell 42, 253–265 | Benguigui et al. | ICH2244 |
| 2024 | Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer | Eur J Nucl Med Mol Imaging | Ketchemen et al. | ICH4013 |
| 2023 | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | Cell Stem Cell 30, 1538–1548 | Gravina et al. | ICH4002 |
| 2023 | Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. | Int. J. Mol. Sci. 2023, 24(22), 16105 | Mancusi et al. | ICH5025 |
| 2023 | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | Front Immunol. 2023; 14: 1311658. | Iadonato et al. | ICH4002 |
| 2023 | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | bioRxiv | Xu et al. | IHC1132 |
| 2023 | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | Journal of Experimental & Clinical Cancer Research | Lee et al. | ICH5015 |
| 2023 | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | Journal for ImmunoTheraphy of Cancer | Travelli et al. | ICH2248 |
| 2023 | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | Narsimhan et al. |
ICH4011, ICH4009, ICH4019
|
| 2023 | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | Cao et al. |
ICH1077, ICH1042, and ICH1043
|
| 2023 | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | Journal of Integrative Medicine | Yang et al. | ICH1128UL |
| 2023 | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | Cytokine | Yuan et al. | ICH1026 |
| 2023 | MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire | European Journal of Immunology | Pircher et al. | ICH1073 |
| 2023 | NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer | Advanced Science | Chen et al. | ICH1086 |
| 2023 | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | Majewska et al. | ICH1086, ICH2243 |
| 2023 | Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice | Cell Reports | Lin et al. | ICH1086 |
| 2023 | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | Journal of Advanced Research | Wu et al. | ICH1132 |
| 2023 | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. | Cancer Research Communications 2023 | Kauffman et al. | ICH1132 |
| 2023 | SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy | bioRxiv | Liang et al. | ICH1132 |
| 2023 | A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles | Nature Communications | Chen et al. | ICH1132UL |
| 2023 | Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression | Nature Biotechnology | Gravina et al. | ICH4002 |
| 2023 | Topical Delivery of Ranibizumab drops in Anti-aggregation diluent formula for retinal Delivery in Rabbits | ARVO Annual Meeting Abstract | Gupta et al. | ICH4031 |
| 2023 | A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity | Journal of Translational Medicine | Huang et al. | ICH5023 |
| 2023 | Vascular Endothelial Growth Factor Receptor 1 Targeting Fusion Polypeptides with Stimuli-Responsiveness for Anti-angiogenesis | ACS Appl. Mater. Interfaces |
Jeong Kang et al.
|
|
| 2023 | Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine | Nature Biomedical Engineering | He et al. | |
| 2022 | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | Nature Communications | Xiong et al. | ICH1114 |
| 2022 | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | Chuah et al. |
ICH1132, ICH1094, ICH1137, ICH2251, ICH2244
|
| 2022 | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | mucosal immunology | Yamazaki et al. | ICH2246 |
| 2022 | SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate | bioRxiv | Lo et al. | ICH4005 |
| 2022 | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | Journal of Tissue Engineering | Pape et al. | ICH4019 |
| 2022 | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | Tikum et al. |
ICH4008, ICH4007
|
| 2022 | Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | Biologics | Dipasquale et al. | ICH4035 |
| 2021 | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | Liu et al. |
ICH1132, ICH2244
|
| 2021 | Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary | Gastroenterology Insights | Parrish II, RH | ICH4035 |
ichorbio Publications for Product Code ICH1026
Citations for Bulk anti-human HLA-DR antibody (L243)
| Yuan et al. | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | Cytokine | 2023 |
ichorbio Publications for Product Code ICH1042
Citations for anti-CD4 In Vivo Antibody - Low Endotoxin (GK1.5)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1043
Citations for ichorbio's anti-CD8 In Vivo Antibody - Low Endotoxin (YTS-169)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1073
Citations for ichorbio's anti-CD40 In Vivo Antibody - Low Endotoxin (FGK4.5)
| Pircher et al. | MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire | European Journal of Immunology | 2023 | ICH1073 |
ichorbio Publications for Product Code ICH1077
Citations for ichorbio's Anti-Mouse CD209b In Vivo Antibody – Low Endotoxin (22D1)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 | ICH1077 |
ichorbio Publications for Product Code ICH1086
Citations for ichorbio's anti-PD-L1 In Vivo Antibody - Low Endotoxin (10F.9G2)
| Chen et al. | NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer | Advanced Science | 2023 | ICH1086 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH1086 |
| Lin et al. | Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice | Cell Reports | 2023 | ICH1086 |
ichorbio Publications for Product Code ICH1094
Citations for ichorbio's anti-CD120a In Vivo Antibody - Low Endotoxin (55R-170)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1094 |
ichorbio Publications for Product Code ICH1114
Citations for ichorbio's anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5)
| Xiong et al. | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | Nature Communications | 2022 | ICH1114 |
ichorbio Publications for Product Code ICH1128UL
Citations for ichorbio's anti-NK1.1 In Vivo Antibody - Low Endotoxin (PK136)
| Yang et al. | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | Journal of Integrative Medicine | 2023 | ICH1128UL |
ichorbio Publications for Product Code ICH1132
Citations for ichorbio's anti-PD-1 (RMP1-14)
| Wu et al. | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | Journal of Advanced Research | 2023 | ICH1132 |
| Kauffman et al. | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. | Cancer Research Communications 2023 | 2023 | ICH1132 |
| Liang et al. | SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1132 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH1132 |
| Chen et al. | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles | Nature Communications | 2023 | ICH1132UL |
ichorbio Publications for Product Code ICH1137
Citations for ichorbio's anti-TNFR2 In Vivo Antibody - Low Endotoxin (TR75-54.7)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1137 |
ichorbio Publications for Product Code ICH2244
Citations for ichorbio's anti-Rat IgG2a isotype control
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2244 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH2244 |
ichorbio Publications for Product Code ICH2246
Citations for ichorbio's Rat IgG1 Isotype Control for In Vivo - Low Endotoxin (GL113)
| Yamazaki et al. | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | mucosal immunology | 2022 | ICH2246 |
ichorbio Publications for Product Code ICH2248
Citations for ichorbio's Mouse IgG1 Isotype Control for In Vivo - Low Endotoxin (HKSP84)
| Travelli et al. | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | Journal for ImmunoTheraphy of Cancer | 2023 | ICH2248 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH2248 |
ichorbio Publications for Product Code ICH2251
Citations for ichorbio's Armenian Hamster IgG Isotype Control for In Vivo - Low Endotoxin (PIP)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2251 |
ichorbio Publications for Product Code ICH4002
Citations for ichorbio's research grade alemtuzumab biosimilar
| Gravina et al. | Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression | Nature Biotechnology | 2023 | ICH4002 |
| Iadonato et al. | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | Front Immunol. 2023; 14: 1311658. | 2023 | ICH4002 |
| Gravina et al. | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | Cell Stem Cell 30, 1538–1548 | 2023 | ICH4002 |
ichorbio Publications for Product Code ICH4005
Citations for ichorbio's Eculizumab Biosimilar - Research Grade
| Lo et al. | SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate | bioRxiv | 2022 | ICH4005 |
ichorbio Publications for Product Code ICH4007
Citations for ichorbio's Matuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4007 |
ichorbio Publications for Product Code ICH4008
Citations for ichorbio's Nimotuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4008 |
ichorbio Publications for Product Code ICH4009
Citations for ichorbio's Nivolumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4009 |
ichorbio Publications for Product Code ICH4011
Citations for ichorbio's Rituximab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4011 |
ichorbio Publications for Product Code ICH4019
Citations for ichorbio's Denosumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4019 |
| Pape et al. | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | Journal of Tissue Engineering | 2022 | ICH4019 |
ichorbio Publications for Product Code ICH4031
Citations for ichorbio's Ranibizumab Biosimilar - Research Grade
| Gupta et al. | Topical Delivery of Ranibizumab drops in Anti-aggregation diluent formula for retinal Delivery in Rabbits | ARVO Annual Meeting Abstract | 2023 | ICH4031 |
ichorbio Publications for Product Code ICH4035
Citations for ichorbio's Vedolizumab Biosimilar - Research Grade
| Dipasquale et al. | Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | Biologics | 2022 | ICH4035 |
| Parrish II, RH | Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary | Gastroenterology Insights | 2021 | ICH4035 |
ichorbio Publications for Product Code ICH5015
Citations for ichorbio's Urelumab Biosimilar - Research Grade
| Lee et al. | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | Journal of Experimental & Clinical Cancer Research | 2023 | ICH5015 |
ichorbio Publications for Product Code ICH5023
Citations for ichorbio's Theralizumab Biosimilar - Research Grade
| Huang et al. | A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity | Journal of Translational Medicine | 2023 | ICH5023 |
